Citius Oncology, Inc. (CTOR) Return on Tangible Equity

CITIUS ONCOLOGY, INC. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

• CITIUS ONCOLOGY, INC. return tang equity for the quarter ending 2026-06-30 was -114.06%, a change of -32.03% year-over-year.
• CITIUS ONCOLOGY, INC. return tang equity for the quarter ending 2026-03-31 was -120.53%, a change of -47.64% year-over-year.
• CITIUS ONCOLOGY, INC. return tang equity for the quarter ending 2025-12-31 was -40.46%, a change of 15.44% year-over-year.
• CITIUS ONCOLOGY, INC. return tang equity for the quarter ending 2025-09-30 was -55.19%, a change of -9.35% year-over-year.
• CITIUS ONCOLOGY, INC. return tang equity for fiscal 2025 was -55.19%, a change of -9.35% from fiscal 2024.
• CITIUS ONCOLOGY, INC. return tang equity for fiscal 2024 was -45.84%.
• CITIUS ONCOLOGY, INC. return tang equity for fiscal 2023 was -121.72%.
• CITIUS ONCOLOGY, INC. return tang equity for fiscal 2023 was -49.72%.